National Cancer Institute (NCI): Sarcoma, Kaposi trials

The registry lists 38 Sarcoma, Kaposi studies with National Cancer Institute (NCI) as lead sponsor. 8 are open to participants now and 9 have results posted.

Phase 1 15Phase 2 18Phase 3 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)RecruitingNCT07308886Phase 2
• Natural History Study of Kaposi SarcomaRecruitingNCT06375122
• Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingNCT05907759Phase 2
• Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingNCT04941274Phase 1/2
• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
• PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaRecruitingNCT04303117Phase 1/2
• Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseRecruitingNCT03300830
• Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruitingNCT00006518
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results posted
• Pomalidomide for Kaposi Sarcoma in People With or Without HIVCompletedNCT01495598Phase 1/2Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Lenalidomide in Treating Patients With AIDS-Associated Kaposi's SarcomaCompletedNCT01057121Phase 1/2Results posted
• Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s SarcomaCompletedNCT00923936Phase 2Results posted
• Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative PatientsCompletedNCT00055237Phase 2Results posted
• Assessment of Blood Vessel Density in Kaposi's Sarcoma LesionsCompletedNCT00026793Results posted
• Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal AnalysisActive, not recruitingNCT04742387
• Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi SarcomaCompletedNCT01016730Phase 1
• Sunitinib Malate in Treating East African Patients With Kaposi SarcomaWithdrawnNCT00521092Phase 2
• Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in SicilyCompletedNCT00339937
• Risk Factors for Non-HIV-Related Kaposi s SarcomaCompletedNCT00339326
• Nicotine Skin Patch in Treating Patients With Kaposi's SarcomaCompletedNCT00295984Phase 2
• BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's SarcomaTerminatedNCT00287495Phase 1
• Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00064142Phase 2
• Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United StatesCompletedNCT00026728
• BMS-275291 in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00024024Phase 1/2
• A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's SarcomaTerminatedNCT00020683Phase 2
• Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
• Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV InfectionCompletedNCT00019240Phase 2
• Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1/2
• Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaCompletedNCT00019123Phase 2
• EMD 121974 in Treating Patients With HIV-Related Kaposi's SarcomaTerminatedNCT00006222Phase 1
• Effects of Potent Antiretroviral Therapy on Kaposi s SarcomaCompletedNCT00006171
• Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
• Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated CancersCompletedNCT00001560
• Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility AntigensCompletedNCT00001294